Skip to main content
. Author manuscript; available in PMC: 2014 Jun 5.
Published in final edited form as: Cancer Cell. 2011 Jul 12;20(1):53–65. doi: 10.1016/j.ccr.2011.06.009

Figure 6. In Vivo Activity of EPZ004777.

Figure 6

(A) H3K79me2 levels were evaluated by immunoblot in subcutaneous MV4-11 tumors derived from untreated animals or animals implanted with pumps containing a 50 mg/ml solution of EPZ004777 for a period of 6 days.

(B) EPZ004777 extends survival of NSG mice after intravenous injection of MV4-11 cells. MV4-11 cells were injected into the tail vein of NSG mice, and animals were implanted with pumps containing vehicle or 50, 100, or 150 mg/ml EPZ004777. Pumps were exchanged once to give a total of 14 days of exposure as indicated. See also Figure S3A.

(C) Complete blood count analysis in C57BL/6 mice treated for 14 days with EPZ004777 or vehicle control. WBC, white blood cell count; NE, neutrophils; LY, lymphocytes; MO, monocytes; Hb, Hemoglobin; Plt, platelets; K/μl, thousands per microliter; M/μl, millions per microliter. N = 5 mice per group, *p < 0.01, all others not significant (p > 0.05).

(D) Effect of 14 days of EPZ004777 treatment on colony formation of hematopoietic progenitors. Five mice per group, all differences not significant (p > 0.05). Error bars represent standard error of the mean. See also Figures S3B–S3D.